The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://declankepo144573.wikiparticularization.com/1991545/retatrutide_vs_tirzepatide_a_comparative_analysis